Abstract 1938P
Background
The prognosis for young patients with papillary thyroid cancer is usually good unless distant metastases occur. Lung metastasis is one of the most common distant metastases of thyroid cancer, but lacks an effective way to predict it. Our aim was to develop a nomogram to predict the possibility of lung metastases in patients with papillary thyroid cancer under 55 years old, considering the genetic background.
Methods
243 patients with papillary thyroid cancer under 55 years old were collected from January 2017 to June 2020 and randomly divided (7:3) into the training (n=170) and validation (n=73) groups. Univariate and multivariate binary logistic regression analyses were conducted, based on which a nomogram related to the risk of lung metastases of thyroid cancer was built in the training group. The nomogram was evaluated by calibration curves and decision curve analysis (DCA), the concordance index (C-index) and area under the receiver operating characteristic (ROC) curve (AUC) in the training and validation groups, respectively.
Results
T stage, Single-side invasion, TERT mutation and BRAF mutation were the independent prognostic factors for the construction of the nomogram. The C-index of the nomogram was 0.89 and 0.88 in the training and validation groups, respectively. The AUC, DAC, and calibration curves for nomogram showed satisfactory results. The cut-off value was 0.229, with a sensitivity of 0.829 and a specificity of 0.793.
Conclusions
A nomogram with good predictive capability has been established and validated, which may do a favor to predict lung metastases of young patients with papillary thyroid cancer in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The science and technology innovation Program of Hunan Province (2023SK4043).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1514P - A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Presenter: Jae Young Lee
Session: Poster session 18
1515P - Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study
Presenter: Ryoji Takada
Session: Poster session 18
1516P - Lung-only metastatic PDAC: Another disease?
Presenter: Léa Mercier
Session: Poster session 18
1517P - Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
Presenter: Giulia Orsi
Session: Poster session 18
1518P - Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial
Presenter: Leonoor Wismans
Session: Poster session 18
Resources:
Abstract
1519P - Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
Presenter: Makoto Ueno
Session: Poster session 18
1520P - Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
Presenter: Andreas Reichinger
Session: Poster session 18
Resources:
Abstract
1521P - Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
Presenter: Hiroshi Imaoka
Session: Poster session 18
1522P - S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Presenter: Yuichiro Tozuka
Session: Poster session 18
1523P - Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Presenter: Yasin Sezgin
Session: Poster session 18